Previous PET studies with [18F]FCWAY were modeled with a 120-min kinetic analysis, using arterial input function with corrections for uptake of the metabolite [18F]fluorocyclohexanecarboxylic acid ([18F]FC) and vascular activity. We evaluated whether logistically less demanding analysis approaches can be used as alternatives to the full analysis. Dynamic frames were acquired for 120-min in 13 temporal lobe epilepsy (TLE) patients and 10 controls, and modeled with a simplified 3-parameter 2-tissue compartment. The gold standard binding index was BPF. Images were also generated with a 90-min (BPF_90) and 60-min (BPF_60) data analysis interval, without correction for [18F]FC (BPF_NOFC) and without neither [18F]FC correction nor vascular correction (BPND_NOFCVA). fP was significantly higher in patients than in controls. BPF_NOFC had very similar statistical power as BPF, except in the raphe where the effect size of BPF_NOFC was about 40% lower than that of BPF. BPND_NOFCVA had poorest performance. Negligible loss of statistical significance in detected differences occurred in the cortex with both BPF_90 and BPF_60, but BPF_60 was associated with some time instability in the raphe. PET scans can be reduced to 90-min in future, arterial line-based, TLE studies. Lack of correction for [18F]FC mildly reduced the statistical power only in the raphe.
CarsonRE.Parameter estimation in positron emission tomography. In: PhelpsMEMazziottaJCSchelbertHR (eds.) Positron emission tomography and autoradiography: principles and applications for the brain and heart. New York: Raven Press, 1986, pp.347–390.
2.
LangLJagodaESchmallB, et al. Development of fluorine-18-labeled 5-HT1A antagonists. J Med Chem1999; 42: 1576–1586.
3.
CarsonRELangLWatabeH, et al. PET evaluation of [18F]FCWAY, an analog of the 5-HT1A receptor antagonist, WAY-100635. Nucl Med Biol2000; 27: 493–497.
4.
CarsonREWuYLangL, et al. Brain uptake of the acid metabolites of F-18-labeled WAY 100635 analogs. J Cereb Blood Flow Metab2003; 23: 249–260.
5.
ToczekMTCarsonRELangL, et al. PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy. Neurology2003; 60: 749–756.
6.
CarsonRELangLFraserC, et al. Human functional imaging with the 5-HT1A ligand [18F]FCWAY. J Nucl Med2002; 43: 55P.
7.
ParseyRVSlifsteinMHwangDR, et al. Validation and reproducibility of measurement of 5-HT1A receptor parameters with [carbonyl-11C]WAY-100635 in humans: comparison of arterial and reference tisssue input functions. J Cereb Blood Flow Metab2000; 20: 1111–1133.
8.
GiovacchiniGToczekMTBonwetschR, et al. 5-HT1A receptors are reduced in temporal lobe epilepsy after partial volume correction. J Nucl Med2005; 46: 1128–1135.
9.
MaYLangLKiesewetterDO, et al. Liquid chromatography-tandem mass spectrometry identification of metabolites of two 5-HT1A antagonists, N-[2-[4-(2-methoxylphenyl)piperazino]ethyl]-N-(2-pyridyl) trans- and cis-4-fluorocyclohexanecarboxamide, produced by human and rat hepatocytes. J Chromatogr B Biomed Sci Appl2001; 755: 47–56.
10.
SawadaYHiragaSPatlakCS, et al. Cerebrovascular transport of [125I]quinuclidinyl benzilate, [3H]cyclofoxy, and [14C]iodoantipyrine. Am J Physiol1990; 258: H1585–1598.
11.
JenkinsonMSmithS.A global optimisation method for robust affine registration of brain images. Med Image Anal2001; 5: 143–156.
12.
CarsonREChanningMABlasbergRG, et al. Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab1993; 13: 24–42.
13.
LammertsmaAABenchCJHumeSP, et al. Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab1996; 16: 42–52.
14.
ParseyRVArangoVOlvetDM, et al. Regional heterogeneity of 5-HT1A receptors in human cerebellum as assessed by positron emission tomography. J Cereb Blood Flow Metab2005; 25: 785–793.
15.
DuvernoyHM.The human hippocampus: functional anatomy, vasculatization and serial sections with MRI. 2nd ed.Berlin, Germany, Springer-Verlag1998.
16.
PhamDLPrinceJL.Adaptive fuzzy segmentation of magnetic resonance images. IEEE Trans Med Imaging1999; 18: 737–752.
17.
InnisRBCunninghamVJDelforgeJ, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab2007; 27: 1533–1539.
18.
HumeSPMyersRBloomfieldPM, et al. Quantitation of carbon-11-labeled raclopride in rat striatum using positron emission tomography. Synapse1992; 12: 47–54.
19.
LammertsmaAAHumeSP.Simplified reference tissue model for PET receptor studies. Neuroimage1996; 4: 153–158.
20.
GunnRNLammertsmaAAHumeSP, et al. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage1997; 6: 279–287.
21.
GunnRNSargentPABenchCJ, et al. Tracer kinetic modeling of the 5-HT1A receptor ligand [carbonyl-11C]WAY-100635 for PET. Neuroimage1998; 8: 426–440.
22.
MerletIOstrowskyKCostesN, et al. 5-HT1A receptor binding and intracerebral activity in temporal lobe epilepsy: an [18F]MPPF-PET study. Brain2004; 127: 900–913.
23.
SavicILindstromPGulyasB, et al. Limbic reductions of 5-HT1A receptor binding in human temporal lobe epilepsy. Neurology2004; 62: 1343–1351.
24.
DidelotARyvlinPLotheA, et al. PET imaging of brain 5-HT1A receptors in the preoperative evaluation of temporal lobe epilepsy. Brain2008; 131: 2751–2764.
25.
ItoSSuharaTItoH, et al. Changes in central 5-HT(1A) receptor binding in mesial temporal epilepsy measured by positron emission tomography with [(11)C]WAY100635. Epilepsy Res2007; 73: 111–118.
26.
LaruelleMvan DyckCAbi-DarghamA, et al. Compartmental modeling of iodine-123-iodobenzofuran binding to dopamine D2 receptors in healthy subjects. J Nucl Med1994; 35: 743–754.
27.
GiovacchiniGLangLMaY, et al. Differential effects of paroxetine on raphe and cortical 5-HT1A binding: a PET study in monkeys. Neuroimage2005; 28: 238–248.
28.
MintunMARaichleMEKilbournMR, et al. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol1984; 15: 217–227.
29.
ParseyRVOquendoMASimpsonNR, et al. Effects of sex, age, and aggressive traits in man on brain serotonin 5-HT1A receptor binding potential measured by PET using [C-11]WAY-100635. Brain Res2002; 954: 173–182.
30.
ParseyRVOgdenRTMillerJM, et al. Higher serotonin 1A binding in a second major depression cohort: modeling and reference region considerations. Biol Psychiatry2010; 68: 170–178.
31.
TheodoreWHGiovacchiniGBonwetschR, et al. The effect of antiepileptic drugs on 5-HT-receptor binding measured by positron emission tomography. Epilepsia2006; 47: 499–503.
32.
van HartenJ. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet1993; 24: 203–220.
33.
DrevetsWCFrankEPriceJC, et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry1999; 46: 1375–1387.
34.
DrevetsWCFrankEPriceJC, et al. Serotonin type-1A receptor imaging in depression. Nucl Med Biol2000; 27: 499–507.
35.
ParseyRVOlvetDMOquendoMA, et al. Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsychopharmacology2006; 31: 1745–1749.
36.
MillerJMHesselgraveNOgdenRT, et al. Brain serotonin 1A receptor binding as a predictor of treatment outcome in major depressive disorder. Biol Psychiatry2013; 74: 760–767.
37.
OquendoMAGalfalvyHSullivanGM, et al. Positron emission tomographic imaging of the serotonergic system and prediction of risk and lethality of future suicidal behavior. JAMA Psychiatry2016; 73: 1048–1055.
38.
NeumeisterABainENugentAC, et al. Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci2004; 24: 589–591.
39.
AznavourNRbahLRiadM, et al. A PET imaging study of 5-HT(1A) receptors in cat brain after acute and chronic fluoxetine treatment. Neuroimage2006; 33: 834–842.
40.
HirvonenJKajanderJAllonenT, et al. Measurement of serotonin 5-HT1A receptor binding using positron emission tomography and [carbonyl-(11)C]WAY-100635-considerations on the validity of cerebellum as a reference region. J Cereb Blood Flow Metab2007; 27: 185–195.
41.
HallHLundkvistCHalldinC, et al. Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]way-100635. Brain Res1997; 745: 96–108.
42.
GiovacchiniGLernerAToczekMT, et al. Brain incorporation of [11C]arachidonic acid, blood volume, and blood flow in healthy aging: a study with partial volume correction. J Nucl Med2004; 45: 1471–1479.
43.
GiovacchiniGConantSHerscovitchP, et al. Using cerebral white matter for estimation of nondisplaceable binding of 5-HT1A receptors in temporal lobe epilepsy. J Nucl Med2009; 50: 1794–1800.
44.
HawkinsRAChoiYHuangSC, et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med1992; 33: 633–642.
45.
MeltzerCCKinahanPEGreerPJ, et al. Comparative evaluation of MR-based partial-volume correction schemes for PET. J Nucl Med1999; 40: 2053–2065.
46.
Muller-GartnerHWLinksJMPrinceJL, et al. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab1992; 12: 571–583.
47.
RyuYHLiowJSZoghbiS, et al. Disulfiram inhibits defluorination of 18F-FCWAY, reduces bone radioactivity, and enhances visualization of radioligand binding to serotonin 5-HT1A receptors in human brain. J Nucl Med2007; 48: 1154–1161.
48.
RabinerEAMessaCSargentPA, et al. A database of [(11)C]WAY-100635 binding to 5-HT(1A) receptors in normal male volunteers: normative data and relationship to methodological, demographic, physiological, and behavioral variables. Neuroimage2002; 15: 620–632.
49.
HillmerATWootenDWBajwaAK, et al. First-in-human evaluation of 18F-mefway, a PET radioligand specific to serotonin-1A receptors. J Nucl Med2014; 55: 1973–1979.
50.
OsmanSLundkvistCPikeVW, et al. Characterization of the radioactive metabolites of the 5-HT1A receptor radioligand, [O-methyl-11C]WAY-100635, in monkey and human plasma by HPLC: comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PET. Nucl Med Biol1996; 23: 627–634.
51.
CostesNMerletIOstrowskyK, et al. A 18F-MPPF PET normative database of 5-HT1A receptor binding in men and women over aging. J Nucl Med2005; 46: 1980–1989.
52.
MoranNFLemieuxLKitchenND, et al. Extrahippocampal temporal lobe atrophy in temporal lobe epilepsy and mesial temporal sclerosis. Brain2001; 124: 167–175.
53.
LiewCJLimYMBonwetschR, et al. 18F-FCWAY and 18F-FDG PET in MRI-negative temporal lobe epilepsy. Epilepsia2009; 50: 234–239.
54.
TheodoreWHMartinezARKhanOI, et al. PET of serotonin 1A receptors and cerebral glucose metabolism for temporal lobectomy. J Nucl Med2012; 53: 1375–1382.
